anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cycle 1 subjects receive SC Azacitidine for first 7 days of 28 day cycle. For Cycle 2 and beyond subjects receive Oral Azacitidine (experimental) for first 7 days of 28 day cycle.
Low back pain is a significant issue in the US Department of Veterans Affairs and Department of Defense populations as well as the general US population at large. This type of pain can be distressing to those who experience its effects, leading patients to seek relief of their symptoms. In 2022, leadership within the US Department of Veterans Affairs and US Department of Defense approved a joint clinical practice guideline for the management of low back pain. The guideline provides evidence-based recommendations for assessing and managing low back pain. Development of the guideline included a systematic evidence review, which was guided by 12 key questions. A multidisciplinary team, which included clinical stakeholders, reviewed the evidence that was retrieved and developed 39 recommendations using the Grading of Recommendations Assessment, Development, and Evaluation system. The scope of the clinical practice guideline is broad; however, the authors have focused on key recommendations that are important for clinicians in the evaluation and nonoperative treatment of low back pain, including pharmacologic therapies and both noninvasive and invasive nonpharmacologic treatments.
The present invention provides a toner for improving roughness of skin. The toner is not tacky, provides pleasant tactility (smoothness in particular), and has excellent stability. Moreover, the present invention particularly provides a skin cleanser for regular and cosmetic uses. That is, the toner of the present invention includes a blocked epoxy derivative represented by formula (I): Y-[O (EO)a-(AO)b-(EO)c-R]k (wherein Y is a residual group of a polyol having 3 to 6 hydroxyl groups after the hydroxyl groups being removed, k is the number of hydroxyl groups in polyol, EO is oxyethylene, AO is oxyalkylene with up to 6 carbons, and they are added in blocks, axk, bxk and cxk are averaged addition mole numbers of oxyethylene, oxyalkylene with 3 to 6 carbons and oxyethylene, respectively, and 0 ≤ axk ≤ 100, 0 ≤ bxk ≤ 100 and 0 ≤ cxk ≤ 100, provided that (a+c)xk > l. Compared with the sum of oxyethylene and oxyalkylene with 3 to 6 carbons, the proportion of oxyalkylene in formula (I) is 10 to 80 mass%. R may be the same or different alkyl groups with 1 to 4 carbons.) The skin cleanser of the present invention has the blocked epoxy derivative represented by formula (I) in an amount of 0.01 to 70 mass% and a humectant in an amount of 0.1 to 20 mass%.
Induction of anesthesia was performed with remifentanil, pentothal 3 mg/kg and atracurium 0.5 mg/Kg. Anaesthesia was maintained with remifentanil (0.4 ug/Kg/min) and isoflurane adjusted to bispectral index (40-60). Patients received a phenylephrine infusion to maintain systolic blood pressure (SBP) 20% to 30% under baseline. The lower limit of SBP was 75 mmHg. In the recovery room, morphine was administered routinely at doses of 3 mg IV every 15 minutes until pain was less than 4 estimated by visual analog scale (VAS). VAS and pain threshold with von Frey filaments were assessed at 2, 6, 12 and 24 postoperative hours. All patients, received ketorolac 30 mg IV every 8 hours and intravenous morphine administered by patient controlled analgesia system (PCA) during the first 24 hours.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In 5 controlled randomized clinical trials, Asclera has been administered to 401 patients with small or very small varicose veins (reticular and spider veins) and compared with another sclerosing agent and with placebo. Patients were 18 to 70 years old. The patient population was predominately female and consisted of Caucasian and Asian patients.

Table 1 shows adverse events more common with Asclera or sodium tetradecyl sulfate (STS) 1% than with placebo by at least 3% in the placebo-controlled EASI study [see Clinical Studies (14)]. All of these were injection site reactions and most were mild.

Ultrasound examinations at one week (±3 days) and 12 weeks (±2 weeks) after treatment did not reveal deep vein thrombosis in any treatment group.
Of the total number of patients enrolled in the POSIMIR clinical studies (N=1463), 167 patients were older than 65 years and 32 patients were older than 75 years. 

In bupivacaine clinical studies, differences in various pharmacokinetic parameters have been observed between elderly and younger adult patients. Bupivacaine is known to be substantially excreted by the kidney, and the risk of adverse reactions to bupivacaine may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Elderly patients may require lower doses of POSIMIR. Consider increased monitoring for local anesthetic systemic toxicity when administering POSIMIR to elderly patients.
PURPOSE: A cosmetic composition from a lotus leaf extract and Eriobotrya japonica is provided to have an excellent antimicrobial effect by having a wide sterilizing spectrum and to have low skin irritation. CONSTITUTION: A polyfunctional sterilizing composition comprises a lotus leaf extract and comprises at least two or more selected from a loquat leaf extract, a loquat seed extract, or a loquat tree extract. A cosmetic composition contains 0.01-80 weight% of the leaf extract. The cosmetic composition is extracted by injecting one of water or organic solvent or a mixture thereof into a mixture of two or more selected from 0.01-20 weight% of the leaf extract, 0.01-20 weight% of the loquat seed extract, and 0.01-20 weight% of the loquat tree extract. The cosmetic composition has a natural sterilization, antibiotic, antioxidant, and anti-aging functions. The cosmetic composition has sterilizing and antibiotic activity by nanocapsules, microcapsules, and nanosomes containing a plant extract.
Anlotinib combined with IBI308. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. IBI308 will be given intravenously at a dose of 200mg every 3 weeks.
PURPOSE: A new variety tea tree with theanine and total amino acid content is provided to improve functionality and preference. CONSTITUTION: A new variety tea tree has characteristics: 3.50% or more of total amino acid content; 2.20% or more of theanine content; 100.0 mg/g or less of total catechin content; and 23.5 mg/g or less of caffeine content. The content of the ingredients is measured by near infrared spectroscopy or high performance liquid chromatography. The leaf width, length, and area of the tea tree is 37-47 mm, 85-95 mm, and 2200-3200 mm^2, respectively. [Reference numerals] (AA) Yabugida; (BB) Jangwon No. 2
BACKGROUND: Assessing pain in infants and neonates is challenging due to their inability to communicate verbally. While validated subjective tools exist, they rely on interpreting the child's behavior, leading to potential inconsistencies and underestimation of pain. Based on heart rate variability, the newborn infant parasympathetic evaluation (NIPE) index offers a more objective approach to pain assessment in children under 2 years. Although promising, research on its effectiveness during surgery under general anesthesia remains limited and inconclusive.
OBJECTIVE: This study compared the effectiveness of NIPE-guided fentanyl administration to traditional vital signs (heart rate and mean arterial pressure) in managing pain during surgery in children under 2 years.
METHODS: Seventy children undergoing head, neck, or upper extremity surgery were randomized into group N (NIPE) or group C (Control) with 35 participants in each group. Both groups received standardized anesthesia and monitoring, including NIPE. Group N received fentanyl when NIPE scores fell below 50, while group C received fentanyl upon a 20% increase in heart rate or mean arterial pressure (MAP). Postoperative pain was assessed using the Face, Legs, Activity, Cry, and Consolability (FLACC) scores, alongside fentanyl consumption, sedation levels, and potential side effects.
RESULTS: Both groups exhibited similar outcomes in terms of postoperative pain scores, fentanyl consumption, sedation levels, and absence of side effects (postoperative respiratory depression or nausea and vomiting). Additionally, intraoperative NIPE scores, heart rate, and MAP were comparable between the groups. There are strong correlations between both groups in terms of NIPE scores (r = 0.735, p < 0.0001), heart rate (r = 0.630, p < 0.0001), and MAP (r = 0.846, p < 0.0001). In both group C and group N, the NIPE scores reveal strong negative correlations with heart rate (r = -0.610, p < 0.0001, and r = -0.674, p < 0.0001) and MAP (r = -0.860, p < 0.0001, and r = -0.756, p < 0.0001).
CONCLUSION: NIPE-guided intraoperative fentanyl administration was not superior to heart rate/MAP-guided administration, as both achieved similar pain management outcomes in this study. However, NIPE may offer a more practical and precise approach, as it is an objective tool with a defined threshold. These findings suggest NIPE's promise as a valuable tool for managing pain in children under 2 years undergoing surgery. However, confirmation of its widespread effectiveness requires further research with larger, multicenter studies encompassing procedures with a broader spectrum of pain severity.
Participants randomized to the sugar pill (control) group will receive placebo. For the purposes of this double-blind trial, placebo (sugar) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.
Type-I photosensitizers have shown advantages in addressing the shortcomings of traditional oxygen-dependent type-II photosensitizers for the photodynamic therapy (PDT) of hypoxic tumors. However, developing type-I photosensitizers is yet a huge challenge because the type-II energy transfer process is much faster than the type-I electron transfer process. Herein, from the fundamental point of view, an effective approach is proposed to improve the electron transfer efficiency of the photosensitizer by lowering the internal reorganization energy and exciton binding energy via self-assembly-induced exciton delocalization. An example proof is presented by the design of a perylene diimide (PDI)-based photosensitizer (PDIMp) that can generate singlet oxygen (1O2) via a type-II energy transfer process in the monomeric state, but induce the generation of superoxide anion (O2˙-) via a type-I electron transfer process in the aggregated state. Significantly, with the addition ofcucurbit[6]uril (CB[6]), the self-assembled PDIMp can convert back to the monomeric state via host-guest complexation and consequently recover the generation of 1O2. The biological evaluations reveal that supramolecular nanoparticles (PDIMp-NPs) derived from PDIMp show superior phototherapeutic performance via synergistic type-I PDT and mild photothermal therapy (PTT) against cancer under either normoxia or hypoxia conditions.
In total 8 different ONS products are consumed and evaluated, each product on a separate test day. The order of products is randomized between study participants.
The invention discloses a novel application of sildenafil, namely an application of sildenafil in preparing medicaments for treating hemangioma. In studies on hemangioma, the inventor accidentally discovers that sildenafil has a remarkable inhibiting effect on proliferation of a vascular endothelial cell which is a main cell component of hemangioma, and has a remarkable promoting effect on apoptosis of the vascular endothelial cell. Therefore, sildenafil can be used as an effective medicament for treating hemangioma, and can be used for preparing medicaments for treating hemangioma. In particular application, the sildenafil can be directly used as a treating medicament for treating hemangioma, and is taken orally. The novel application of the sildenafil in treating hemangioma belongs to novel application of discovered medicaments, and is discovered by accident. The discovery is not noticeable, and has an important application value and meaning.
Ferroptosis has been recognized as a critical factor in the development of atrial fibrillation (AF), but its precise mechanisms remain unclear. We downloaded the GSE115574 dataset from the gene expression omnibus database to analyze the expression levels of ferroptosis-related genes (FRGs) and identify differentially expressed genes (DEGs). Least absolute shrinkage and selection operator (LASSO) and support vector machine-recursive feature elimination (SVM-RFE) machine learning techniques were employed to identify key genes associated with AF. The diagnostic performance of these genes was evaluated using Receiver operating characteristic curves (ROC) and validated in an independent AF dataset. miRNA and lncRNA predictions for potential binding to these key genes were conducted using miRBase, miRDB, and TargetScan. Furthermore, gene set enrichment analysis (GSEA) enrichment analysis, immune cell infiltration analysis, and targeted drug prediction were performed. The intersection of LASSO regression and SVM-RFE analyses identified 7 DEGs significantly associated with AF. Validation through ROC and an additional dataset confirmed the importance of MAPK14, CAV1, and ADAM23. Significant infiltration of memory B cells, regulatory T cells, and monocytes was observed in atrial tissues. Seventy-two miRNAs were predicted to potentially target MAPK14, and 2 drugs were identified as targeting CAV1. This study underscores the involvement of FRGs in AF through machine learning and validation approaches. The observed immune cell infiltration suggests a potential link between immune response and AF. The predicted ceRNA network offers new insights into gene regulation, presenting potential biomarkers and therapeutic targets for AF.
BACKGROUND: Gastro-esophageal reflux disease (GERD/GORD) is a chronic condition in which gastric acid flows backwards up into the esophagus, causing heart burn and a higher disposition to esophageal cancer. The reflux is caused by impairment of the lower esophageal sphincter (LES). Over the past century gastro-esophageal reflux has become the principal gastrointestinal condition of our time. The proton pump inhibitor class of drugs is effective in ameliorating the symptoms of reflux. The cost of investigation of patients in Europe is €100 billion per annum. The cost in days lost from work is €100 billion per annum in Europe. The global cost is 3 times this amount.
METHODOLOGY: The proposed device for treating gastro-esophageal reflux is a biodegradable valve that is placed non surgically in the esophago-gastric junction to prevent reflux from the stomach to the esophagus.
EXPERIMENT RESULTS: 50 simulator studies were performed with the patented device to elucidate the most consistent method of insertion and fixation in a human like simulator. The simulator was designed to replicate the normal human gastro-esophageal anatomy and characteristics. Four animal insertions were performed under ethical regulation at Amsterdam Medical Centre, Netherlands. Three cadaveric experiments were performed at Hackensack University Hospital, New Jersey, USA, to verify the positive outcomes of the simulator studies.
CONCLUSION: Successful outcomes of simulator studies and cadaveric experiments allowed the design freeze of a NoReflux device for treating gastro-esophageal reflux disease.
<P>PROBLEM TO BE SOLVED: To rapidly execute high-quality clinical trial by sharing information about a CRC and a doctor by a a clinical test department of a university hospital to perform a clinical trial task of an SMO with high efficiency and high quality.  <P>SOLUTION: In this clinical trial management system, when a clinical trial execution server 2 receives clinical trial request data from a clinical trial request server 1, the clinical execution server 2 notifies execution organization servers 3, 4 and 5 about the clinical trial request data, and receives the clinical trial application data from the execution organization servers 3, 4 and 5. When receiving the clinical trial application data, the clinical trial execution of the execution organization servers 3, 4 and 5 is registered, clinical trial protocols are executed on the execution organization server 3, 4 and 5 sides, and the decision of a clinical trial result is performed by decision request data. Clinical trial-related data obtained by the clinical trial execution are updated such that the data can be used for the later clinical trial, fed back, and registered in databases DB 13, 14 and 15. When receiving cost payment data from a clinical trial request server 1, clinical trial processing is ended.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The circadian clock system, an evolutionarily conserved mechanism, orchestrates diurnal rhythms in biological activities such as behavior and metabolism, aligning them with the earth's 24-hour light/dark cycle. This synchronization enables organisms to anticipate and adapt to predictable environmental changes, including nutrient availability. However, modern lifestyles characterized by irregular eating and sleeping habits disrupt this synchrony, leading to metabolic disorders such as obesity and metabolic syndrome, evidenced by higher obesity rates among shift workers. Conversely, circadian disturbances are also associated with reduced nutrient absorption and an increased risk of malnutrition in populations such as the critically ill or the elderly. The precise mechanisms of these disturbances in leading to either overnutrition or undernutrition is complex and not yet fully understood. Glucose, a crucial energy source, is closely linked to obesity when consumed excessively and to weight loss when intake is reduced, which suggests that circadian regulation of glucose metabolism is a key factor connecting circadian disturbances with nutritional outcomes. In this review, we describe how the biological clock in various tissues regulates glucose metabolism, with a primary focus on studies utilizing animal models. Additionally, we highlight current clinical evidence supporting the association between circadian disturbance and glucose metabolism, arguing that such disruption could predominantly contribute to undernutrition due to impaired efficient utilization of nutrients.
PCT No. PCT/AU90/00603 Sec. 371 Date Oct. 11, 1991 Sec. 102(e) Date Oct. 11, 1991 PCT Filed Dec. 20, 1990 PCT Pub. No. WO91/09124 PCT Pub. Date Jun. 27, 1991.Variants of the plasminogen activator inhibitor PAI-2 in which the 66-98 amino acid residue region has been altered to eliminate at least one protease sensitive site are provided. The variants of the invention maintain the biological activity of PAI-2 and amino acids up to 65 and from 99 of PAI-2 in frame. The PAI-2 variants of the invention in labelled form, as well as DNA molecules encoding the variants of the invention, transformed host cells expressing the variants of the invention compositions and diagnostic kits comprising the variants of the invention, antibodies against the variants of the invention and processes for the production of the variants, DNA molecules, transformed hosts, compositions and antibodies of the invention are also described.
The cancer invasion of the large intestine, a destructive process that begins within the mucous membrane, causes cancer cells to gradually erode specific layers of the intestinal wall. The normal tissues of the intestine are progressively replaced by a tumour mass, leading to the impairment of the large intestine's proper morphology and function. At the ultrastructural level, the disintegration of the extracellular matrix (ECM) by cancer cells triggers the activation of inflammatory cells (macrophages) and connective tissue cells (myofibroblasts) in this area. This accumulation and the functional interactions between these cells form the tumour microenvironment (TM). The constant modulation of cancer cells and cancer-associated fibroblasts (CAFs) creates a specific milieu akin to non-healing wounds, which induces colon cancer cell proliferation and promotes their survival. This review focuses on the processes occurring at the "front of cancer invasion", with a particular focus on the role of the desmoplastic reaction in neoplasm development. It then correlates the findings from the microscopic observation of the cancer's ultrastructure with the potential of modern radiological imaging, such as computer tomography (CT) and magnetic resonance imaging (MRI), which visualizes the tumour, its boundaries, and the tissue reactions in the large intestine.
The present invention relates to a method for preparing a micro pill by using the liquid extracts of Chinese patent medicines, and a micro-pill making machine. The micro pill is prepared form the liquid extracts of Chinese patent medicines and excipients. The present invention is characterized in that many steps of stripping, forming, rolling, the coating of surfaces, drying, etc., are completed by the micro-pill making machine comprising a pill making device (1), a feeding system (2) and a powder recovery system (3) by the liquid extract and the excipients, and the micro pill with the pill diameter of 2.500mm to 0.250mm is manufactured. The present invention has the following advantages of simple technical process, smooth and compact surfaces of the micro pill, and great bulk density. The present invention breaks through that the micro pill is directly prepared by the liquid extracts of the traditional Chinese medicine only by a method of water pills; the excipients are not contained; or a few excipients are contained, and the dosage is small. The present invention is convenient to realize the automation of the micro-pill technologies. The method for preparing the liquid extracts of Chinese patent medicines enters modernization and starts a new path for the development of micro pills.
There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + Placebo, followed by LDOPS + ENT, and lastly LDOPS + CAR.